8 September 2014

ASX ANNOUNCEMENT

ImpediMed (ASX:IPD)

Leading US Oncologist Dr Frank A. Vicini Joins ImpediMed Team

ImpediMed (ASX:IPD) is pleased to announce today the appointment of Dr Frank A. Vicini, MD, FACR as its first Chief Medical Officer.

The American Medical Association recently released a new CPT® I code for lymphoedema assessment. As a result, Dr Vicini has joined ImpediMed to provide oncology expertise and leadership across the company and act as an advisor to future business development and strategy. He will also support ImpediMed’s medical education and publication strategies.

Dr Vicini is an internationally-recognized radiation oncologist. He has extensive experience in cancer clinical trial design and implementation. Dr Vicini has held multiple academic appointments, authored over 200 peer-reviewed articles and been involved in numerous clinical studies focusing on cancer treatment. He is currently the Co-Investigator of the ImpediMed L-Dex international post-approval clinical study and the Principal Investigator of several National Institutes of Health (NIH) trials with the goal of improving therapeutic outcomes for all stages of breast cancer, reducing treatment times and minimizing toxicities of healthy tissues and vital organs. He is also listed in “Best Oncology Doctors in America”.

“Dr Vicini’s extensive leadership experience in oncology made him the clear choice for our CMO position”, said Richard Carreon, President and CEO of ImpediMed. “Dr Vicini shares our vision of addressing the issues of early lymphoedema detection and early intervention through strong partnerships and focused patient care, and I am confident he will be a significant contributor to our success as we pursue the goal of preventing late-stage lymphoedema.”

Dr Vicini commented, "I am very pleased to be joining ImpediMed to address a serious need among cancer survivors at risk of developing lymphoedema with improved early detection and early treatment of this devastating condition. I share with ImpediMed the belief that L-Dex has the potential to set a new standard of care in the goal of preventing advanced clinical lymphoedema, and to improve the lives of cancer survivors worldwide."

ENDS

For further information contact:
Richard Carreon, ImpediMed CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Kyahn Williamson, Buchan
Investor and Media Relations
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au